Braskem Expands Its Own Fleet with the Vessel Brave Future and Strengthens its Global Logistics Strategy
The ethane carrier has a length of 188 meters, a capacity of 36,000 m³, and is capable of transporting cargo at temperatures as low as -104°C, it was financed by Ocean Yield and will be operated by the Hartmann Reederei. The vessel is equipped with a dual-fuel engine running on bunker oil and ethane. It boasts high fuel efficiency and a propulsion system with CO₂ emissions approximately 40% lower than the average fleet in operation.
'The Brave Future is a strategic asset that expands our autonomy in the area of logistics, which provides greater predictability to operations, and strengthens our position as a global leader in the petrochemical industry,' highlights Hardi Schuck, Director of Braskem Trading & Shipping (BT&S). Before the christening, the vessel underwent sea trials, a rigorous testing phase at sea that evaluates safety, speed, maneuverability, and equipment performance before the start of commercial operations.
With the new vessel, Braskem now has two dedicated ethane carriers – the Brave Future and the Brilliant Future. In 2026, BT&S expects the delivery of four more ships to serve Braskem. This structure reinforces the company's commitment to innovative, sustainable logistics solutions aligned with the demands of global maritime trade.
About Braskem
Braskem is a global, human-oriented petrochemical company with a forward-looking approach, cultivating strong relationships and generating value for all. Offering sustainable chemical and plastic solutions to improve people's lives, the company has a comprehensive portfolio of plastic resins and chemical products for various sectors, including food packaging, civil construction, industrial, automotive, agribusiness, health, and hygiene, among others. Braskem believes that disruptive innovation is the only viable path to establishing a new relationship with the planet. Therefore, it chooses to act in the present by promoting plastic circularity and driving the revolution of bio-based materials. With 40 industrial units in Brazil, the USA, Mexico, and Germany, the company exports its products to customers in over 71 countries through its 8,500 team members who operate globally under a management model that demonstrates a commitment to ethics, compliance with regulations in all countries, and respect for responsible competitiveness.
Braskem on English social media:
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
an hour ago
- Yahoo
Trump Says 200% Pharma Tariffs Are Coming. Wall Street Shrugs.
When a U.S. president threatens your industry with a 200% tariff, that's not typically good news. But since Tuesday, when Donald Trump said in a cabinet meeting that imported pharmaceuticals would face a massive levy, investors have been cautiously celebrating. Despite a broad stock selloff on Friday, the NYSE Arca Pharmaceutical Index is up around 1% over the past week, compared with a basically flat performance for the S&P 500. Inside the Shadowy, Lucrative Business of 'Superfake' Luxury Handbags SpaceX to Invest $2 Billion Into Elon Musk's xAI The Best EV Deals Now Are on the Used Market That outperformance may seem puzzling, but for Wall Street, the size of the tariff matters less than the timing. The 200% figure lit up cable news chyrons, but investors focused instead on the grace period Trump floated. 'We're going to give people about a year, year and a half to come in, and after that, they're going to be tariffed,' he said. A year and a half is a long runway—and it could turn out to be even longer in practice. In a note titled 'Tariffs Schmariffs,' Jefferies analyst Akash Tewari argues that if the grace period begins some time this year and lasts for a year and a half, companies could continue importing drugs tariff-free until 2027. They could buy even more time if they stockpile during that period to cover demand at least until some time in 2028. That might give them time to build entirely new U.S. manufacturing facilities, which typically takes around four years. This doesn't mean Trump isn't getting what he wants. After all, the tariffs are meant as a threat to push companies to make more of their products in the U.S. And in this case, the threat seems to be working. Since Trump began threatening pharma with tariffs, the industry has moved on two fronts. First, companies have been stockpiling drugs at a furious pace to build a cushion. For instance, the Wall Street Journal reported last month that $36 billion worth of hormone treatments—used in popular obesity and diabetes drugs—have been shipped from Ireland this year, more than double last year's total. Second, the industry has announced major investments in U.S. manufacturing. Some of that may be political posturing, but much of it reflects a real shift. Companies increasingly see no choice but to bring production back, at least for drugs sold to American patients. Eli Lilly, for example, has announced a $27 billion plan to expand manufacturing in the U.S. Making drugs in the U.S.—and registering the intellectual property here—comes with a tax hit. That is a big reason the industry offshored production to low-tax countries like Ireland in the first place. But Trump's 'Big Beautiful Bill' offers some relief to offset the pain. The bill lets companies immediately deduct R&D expenses and equipment purchases and raises the cap on how much interest they can write off—making it a lot cheaper to build new plants at home. The upshot: with more time to prepare and a friendlier tax environment, pharma companies may barely feel the sting of tariffs. Take Merck. The company plans to produce a new version of its blockbuster drug Keytruda in the U.S. Jefferies estimates that with steps like stockpiling, gradually shifting production and trimming some costs, the hit to Merck's earnings from tariffs in 2027 and 2028 could be just 1% to 2%. That is actually better than Jefferies's earlier model for a smaller 25% tariff, which assumed fewer workarounds. The sense of a new normal settling in around Trump's second presidency might help explain why dealmaking has returned to the sector. Merck this past week announced a roughly $10 billion deal to buy Verona Pharma. That followed a series of other deal announcements, including Eli Lilly's $1.3 billion pact to acquire Verve Therapeutics. By the end of Trump's term, the U.S. pharmaceutical supply chain could look very different, with a greater share of innovative drug production happening on American soil. That would be a rare win-win—for the White House and for the industry. Write to David Wainer at Economists See Lower Recession Risk and Stronger Job Growth: WSJ Survey Can Pittsburgh's Old Steel Mills Be Turned Into an AI Hub? Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
an hour ago
- Yahoo
4 No-Brainer Blue Chip Stocks to Buy With $2,000 Right Now
Blue chip companies have established sound business models that can deliver solid returns over time. These companies often operate in stable industries with steady demand for their services. They also tend to display a strong economic moat through pricing power and barriers to entry. 10 stocks we like better than Berkshire Hathaway › Investing in the stock market is one way to build enduring, long-term wealth. As an investor, you could choose to invest in high-flying growth stocks, dividend stocks that provide passive income, or more conservative investments that can preserve and grow your investments steadily over time. One strategy you can consider is investing in blue chip companies. These companies have withstood the test of time thanks to sound business models that have led to solid returns for patient investors. Blue chips typically offer reliable dividends and steady long-term growth, making them appealing to both seasoned investors and newcomers seeking to establish a solid financial foundation. Here are four blue chip stocks you can invest in today. Berkshire Hathaway (NYSE: BRK.A) (NYSE: BRK.B) has thrived under the leadership of its longtime CEO, Warren Buffett. Since 1965, Buffett has led the conglomerate to 20% annualized returns, or enough to turn a $100 investment into $5.5 million today. So when Buffett announced earlier this year he was stepping down at the end of 2025, it took the wind out of the sails of Berkshire Hathaway stock, which is down 12% since the announcement in early May. However, Berkshire Hathaway is a widely diversified conglomerate with holdings across numerous industries, including insurance, transportation, materials, consumer goods, and energy. Its insurance operations help generate a steady stream of cash flow, which it can invest in treasuries or equities, or use to acquire companies outright. What makes Berkshire appealing right now is its massive cash pile and positive tailwinds from higher interest rates. The Federal Reserve is cautious about cutting interest rates due to concerns about inflation stemming from higher tariffs. This has resulted in rates staying "higher for longer," and Berkshire has benefited to the tune of $2.9 billion in interest income in the first quarter. Berkshire will be under new leadership, led by CEO Greg Abel, with its investment portfolio managed by Todd Combs and Ted Weschler, the investing lieutenants tapped by Buffett and the late Charlie Munger over a decade ago. While the uncertainty around its future remains, I think it's well-capitalized and diversified enough that it's a buy at today's price. Progressive (NYSE: PGR) is the second-largest automotive insurer in the United States. What sets this blue chip company apart is its disciplined underwriting, strong brand, and direct-to-consumer model. The company relies heavily on technology and data to accurately price risk and was one of the original companies to adopt usage-based insurance, known as telematics. This approach utilizes driver data to price policies, which is one reason the company has outperformed its competitors. Progressive's track record of navigating underwriting cycles while maintaining profitability distinguishes it. Going back 23 years, the company's combined ratio has averaged 92%, which is significantly lower than the industry average of 100%. Put differently, Progressive has earned an average of $8 in underwriting profit for every $100 in premiums. As a stock, Progressive offers defensive characteristics with upside. Insurance is a stable industry that enjoys steady demand, and Progressive has demonstrated its ability to outperform its peers in underwriting profitability. The company is also well-positioned to perform if inflation and interest rates were to remain elevated. That's because it has pricing power, allowing it to adapt to rising costs, and it also earns interest on float (the cash it collects from premiums but hasn't yet paid out in claims). Its stellar long-term performance and ongoing strong underwriting make Progressive an excellent blue chip stock to consider adding to your portfolio today. Chubb (NYSE: CB) is one of the world's largest publicly traded property and casualty insurers, recognized for its underwriting discipline, global diversification, and robust balance sheet. It operates across commercial and personal lines, with a reputation for serving high-net-worth individuals and complex corporate risks. Its conservative approach to risk, coupled with a broad international footprint, has enabled it to weather economic cycles well. Chubb has been a solid dividend stock for investors, growing its payout for 32 consecutive years. With a yield of 1.4% and an average annual total return of 11.7% over the past two decades, the company offers investors a balanced combination of income and stock price appreciation. It also enjoys the benefits that Progressive does, such as pricing power and interest income, making it another solid blue chip stock to consider owning today. S&P Global (NYSE: SPGI) plays a key role in markets. The company is perhaps best known for its S&P 500 index, but it also provides credit ratings, data, and analytics. Barriers to entry make it difficult to break into the credit ratings space, and S&P Global holds a 50% share of this market. S&P Global's business model is resilient and scalable. Credit rating demand rises with bond issuance, while its index and data segments enjoy recurring fees from ETF licensing and subscriptions. The company also has low capital requirements, which enables it to enjoy high margins, recurring revenue, and a global reach. The company has raised its dividend payout for 53 years, making it an exclusive member of the Dividend Kings club. While it offers a modest dividend yield of 0.7%, when combined with its stock price appreciation, S&P Global has returned 15.3% annually over the past two decades. For investors, S&P Global offers growth and a wide moat along with steady cash flows, making it a quality blue chip stock to own today. Before you buy stock in Berkshire Hathaway, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and Berkshire Hathaway wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $671,477!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $1,010,880!* Now, it's worth noting Stock Advisor's total average return is 1,047% — a market-crushing outperformance compared to 180% for the S&P 500. Don't miss out on the latest top 10 list, available when you join . See the 10 stocks » *Stock Advisor returns as of July 7, 2025 Courtney Carlsen has positions in Berkshire Hathaway and Progressive. The Motley Fool has positions in and recommends Berkshire Hathaway, Progressive, and S&P Global. The Motley Fool has a disclosure policy. 4 No-Brainer Blue Chip Stocks to Buy With $2,000 Right Now was originally published by The Motley Fool Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
an hour ago
- Yahoo
Are Investors Undervaluing Cable One, Inc. (NYSE:CABO) By 29%?
Cable One's estimated fair value is US$176 based on 2 Stage Free Cash Flow to Equity Current share price of US$125 suggests Cable One is potentially 29% undervalued The US$250 analyst price target for CABO is 42% more than our estimate of fair value How far off is Cable One, Inc. (NYSE:CABO) from its intrinsic value? Using the most recent financial data, we'll take a look at whether the stock is fairly priced by projecting its future cash flows and then discounting them to today's value. This will be done using the Discounted Cash Flow (DCF) model. It may sound complicated, but actually it is quite simple! We generally believe that a company's value is the present value of all of the cash it will generate in the future. However, a DCF is just one valuation metric among many, and it is not without flaws. If you want to learn more about discounted cash flow, the rationale behind this calculation can be read in detail in the Simply Wall St analysis model. We've found 21 US stocks that are forecast to pay a dividend yield of over 6% next year. See the full list for free. We're using the 2-stage growth model, which simply means we take in account two stages of company's growth. In the initial period the company may have a higher growth rate and the second stage is usually assumed to have a stable growth rate. In the first stage we need to estimate the cash flows to the business over the next ten years. Where possible we use analyst estimates, but when these aren't available we extrapolate the previous free cash flow (FCF) from the last estimate or reported value. We assume companies with shrinking free cash flow will slow their rate of shrinkage, and that companies with growing free cash flow will see their growth rate slow, over this period. We do this to reflect that growth tends to slow more in the early years than it does in later years. Generally we assume that a dollar today is more valuable than a dollar in the future, and so the sum of these future cash flows is then discounted to today's value: 2026 2027 2028 2029 2030 2031 2032 2033 2034 2035 Levered FCF ($, Millions) US$257.8m US$179.0m US$146.0m US$105.0m US$84.9m US$74.3m US$68.5m US$65.3m US$63.8m US$63.3m Growth Rate Estimate Source Analyst x6 Analyst x1 Analyst x1 Analyst x1 Est @ -19.12% Est @ -12.50% Est @ -7.87% Est @ -4.63% Est @ -2.36% Est @ -0.77% Present Value ($, Millions) Discounted @ 12% US$231 US$144 US$105 US$67.7 US$49.1 US$38.5 US$31.8 US$27.1 US$23.7 US$21.1 ("Est" = FCF growth rate estimated by Simply Wall St)Present Value of 10-year Cash Flow (PVCF) = US$739m After calculating the present value of future cash flows in the initial 10-year period, we need to calculate the Terminal Value, which accounts for all future cash flows beyond the first stage. The Gordon Growth formula is used to calculate Terminal Value at a future annual growth rate equal to the 5-year average of the 10-year government bond yield of 2.9%. We discount the terminal cash flows to today's value at a cost of equity of 12%. Terminal Value (TV)= FCF2035 × (1 + g) ÷ (r – g) = US$63m× (1 + 2.9%) ÷ (12%– 2.9%) = US$752m Present Value of Terminal Value (PVTV)= TV / (1 + r)10= US$752m÷ ( 1 + 12%)10= US$251m The total value, or equity value, is then the sum of the present value of the future cash flows, which in this case is US$990m. In the final step we divide the equity value by the number of shares outstanding. Relative to the current share price of US$125, the company appears a touch undervalued at a 29% discount to where the stock price trades currently. Valuations are imprecise instruments though, rather like a telescope - move a few degrees and end up in a different galaxy. Do keep this in mind. Now the most important inputs to a discounted cash flow are the discount rate, and of course, the actual cash flows. Part of investing is coming up with your own evaluation of a company's future performance, so try the calculation yourself and check your own assumptions. The DCF also does not consider the possible cyclicality of an industry, or a company's future capital requirements, so it does not give a full picture of a company's potential performance. Given that we are looking at Cable One as potential shareholders, the cost of equity is used as the discount rate, rather than the cost of capital (or weighted average cost of capital, WACC) which accounts for debt. In this calculation we've used 12%, which is based on a levered beta of 2.000. Beta is a measure of a stock's volatility, compared to the market as a whole. We get our beta from the industry average beta of globally comparable companies, with an imposed limit between 0.8 and 2.0, which is a reasonable range for a stable business. Check out our latest analysis for Cable One Strength Debt is well covered by earnings. Weakness No major weaknesses identified for CABO. Opportunity Expected to breakeven next year. Has sufficient cash runway for more than 3 years based on current free cash flows. Good value based on P/S ratio and estimated fair value. Significant insider buying over the past 3 months. Threat Debt is not well covered by operating cash flow. Revenue is forecast to decrease over the next 2 years. Although the valuation of a company is important, it is only one of many factors that you need to assess for a company. The DCF model is not a perfect stock valuation tool. Rather it should be seen as a guide to "what assumptions need to be true for this stock to be under/overvalued?" If a company grows at a different rate, or if its cost of equity or risk free rate changes sharply, the output can look very different. Can we work out why the company is trading at a discount to intrinsic value? For Cable One, there are three additional factors you should assess: Risks: Every company has them, and we've spotted 2 warning signs for Cable One (of which 1 is concerning!) you should know about. Future Earnings: How does CABO's growth rate compare to its peers and the wider market? Dig deeper into the analyst consensus number for the upcoming years by interacting with our free analyst growth expectation chart. Other High Quality Alternatives: Do you like a good all-rounder? Explore our interactive list of high quality stocks to get an idea of what else is out there you may be missing! PS. Simply Wall St updates its DCF calculation for every American stock every day, so if you want to find the intrinsic value of any other stock just search here. Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Sign in to access your portfolio
